NASDAQ:MNKD
MannKind Corporation Stock News
$4.59
+0 (+0%)
At Close: May 17, 2024
MannKind's stock falls 18% after FDA says it will not approve application for hypertension drug
11:42am, Monday, 18'th Oct 2021
Shares of MannKind Corp. MNKD, -17.68% tumbled 18.3% in trading on Monday after the company said the Food and Drug Administration would not approve a pulmonary arterial hypertension treatment it is de
Why MannKind Shares Are Falling Today
09:20am, Monday, 18'th Oct 2021
MannKind Corp (NASDAQ: MNKD) is trading significantly lower Monday morning after the company announced the FDA issued a complete response to United Therapeutics regarding the New Drug Application for
FDA Declines MannKind - United Therapeutics' Formulated Treprostinil For Lung Disease
08:45am, Monday, 18'th Oct 2021
The FDA has issued a complete response to United Therapeutics Corporation (NASDAQ: UTHR) regarding the marketing application for Tyvaso DPI for pulmonary arterial hypertension (PAH) and pulmonary
Progress Update on Tyvaso DPI™ New Drug Application
06:00am, Monday, 18'th Oct 2021
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., Oct. 18, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic pr
MannKind Corporation (MNKD) CEO Mike Castagna Presents at Lytham Partners Fall Conference (Transcript)
02:55pm, Tuesday, 05'th Oct 2021
MannKind Corporation (MNKD) CEO Mike Castagna Presents at Lytham Partners Fall Conference (Transcript)
Do Options Traders Know Something About MannKind (MNKD) Stock We Don't?
09:29am, Monday, 04'th Oct 2021
Investors need to pay close attention to MannKind (MNKD) stock based on the movements in the options market lately.
MannKind Announces First Patient Enrolled In Inhale-1 Study Of Afrezza® In Pediatric Population
07:05am, Monday, 04'th Oct 2021
WESTLAKE VILLAGE, Calif., Oct. 4, 2021 /PRNewswire/ -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients wit
5 Penny Stocks To Watch This Week With Potential Biotech Catalysts
10:45am, Sunday, 03'rd Oct 2021
Will upcoming events mean big things for these penny stocks? The post 5 Penny Stocks To Watch This Week With Potential Biotech Catalysts appeared first on Penny Stocks to Buy, Picks, News and Informat
Mannkind Corporation Announces Sale-Leaseback Transaction Generating $102.25 Million in Non-Dilutive Gross Proceeds
04:24pm, Wednesday, 29'th Sep 2021
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., Sept. 29, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic p
MannKind Corporation to Participate at Lytham Partners Fall 2021 Investor Conference
06:05am, Tuesday, 28'th Sep 2021
WESTLAKE VILLAGE, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patient
MannKind Corporation (MNKD) CEO Michael Castagna Presents at Cantor Global Healthcare 2021 Conference (Transcript)
03:32pm, Monday, 27'th Sep 2021
MannKind Corporation (MNKD) CEO Michael Castagna Presents at Cantor Global Healthcare 2021 Conference (Transcript)
MannKind Corporation (MNKD) CEO Michael Castagna Presents at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit (Transcript)
06:48pm, Wednesday, 22'nd Sep 2021
MannKind Corporation (MNKD) CEO Michael Castagna Presents at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit (Transcript)
Mannkind Corporation Participating at Upcoming Conferences
06:05am, Wednesday, 15'th Sep 2021
WESTLAKE VILLAGE, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patient
MannKind Corporation (MNKD) CEO Michael Castagna Presents at H.C. Wainwright 23rd Annual Global Investment Brokers Conference (Transcript)
United Therapeutics-MannKind's Formulated Tyvaso Shows Benefit In Pulmonary Hypertension Patients
09:54am, Tuesday, 07'th Sep 2021
United Therapeutics Corporation (NASDAQ: UTHR) has presented new clinical data from the BREEZE study evaluating Tyvaso DPI (treprostinil) in patients with pulmonary arterial hypertension (PAH). Rel
